E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
The court found that Ceban infringed Novo Nordisk’s supplementary protection certificate covering semaglutide and ordered it to cease the infringing activities.
imphoenix82
Novo Nordisk alleges Lilly’s advertisements for Zepbound and Mounjaro mislead consumers by comparing the drugs with lower-dose versions of Wegovy and Ozempic.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
